TYMS Antibody

What is TYMS and why is it significant for cancer research?

Thymidylate synthetase (TYMS) is a 36 kDa enzyme (EC 2.1.1.45) that catalyzes the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), which is essential for DNA biosynthesis . TYMS is significant in cancer research for several reasons:

• It serves as a critical target for fluoropyrimidines, an important group of antineoplastic drugs widely used in treating solid tumors

• The expression of TYMS protein has been associated with response to 5-fluorouracil (5-FU) treatment in human colorectal, gastric, head and neck, and breast carcinomas

• TYMS is an important factor in the growth of tumor cells, making it both a therapeutic target and potential biomarker

Methodologically, researchers studying TYMS should consider its dual role as both a cancer biomarker and drug target when designing experiments to evaluate treatment efficacy or cancer progression.

What applications are TYMS antibodies validated for?

TYMS antibodies have been validated for multiple research applications, with different products showing specific validation profiles:

When selecting an application, researchers should consider that antibody performance can vary between cell lines and tissue types. For example, positive Western blot detection has been reported in HEK-293, HepG2, and Jurkat cells, while positive IHC has been observed in human pancreas and colon cancer tissues .

How should samples be prepared for optimal TYMS antibody performance in IHC?

For optimal performance in immunohistochemistry applications using TYMS antibodies, sample preparation is critical:

• Antigen retrieval recommendations:

  • Primary recommendation: Use TE buffer at pH 9.0 for antigen retrieval

  • Alternative method: Citrate buffer at pH 6.0 can also be used

• Antibody concentration:

  • Typical working dilution range for IHC: 1:200-1:800

  • For azide-free formulations: 1-2 μg/mL is recommended

• Detection systems:

  • Paraffin-embedded tissues are commonly used with TYMS antibodies

  • Consider titrating the antibody in each testing system to obtain optimal results

• Control tissues:

  • Human pancreatic cancer and colon cancer tissues have shown positive detection and can serve as positive controls

The choice of buffer and retrieval method may significantly impact antibody binding efficiency and should be optimized for each specific experimental context.

What are the recommended storage conditions for TYMS antibodies?

Proper storage of TYMS antibodies is essential for maintaining their reactivity and specificity over time:

• Temperature requirements:

  • Store at -20°C for standard preparations

  • Some formulations require storage at -20°C to -80°C

• Buffer composition:

  • Typical storage buffer: PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

  • Some antibody formulations are available as azide-free and BSA-free options

• Stability period:

  • Most preparations remain stable for one year after shipment when stored properly

  • Avoid repeated freeze-thaw cycles as this can degrade antibody performance

• Aliquoting considerations:

  • For -20°C storage, aliquoting is generally unnecessary

  • Small volume products (20 μL) may contain 0.1% BSA as a stabilizer

Researchers should carefully follow manufacturer-specific storage recommendations as formulations can vary between suppliers.

Which cell lines and tissues have demonstrated positive reactivity with TYMS antibodies?

When designing experiments with TYMS antibodies, choosing appropriate positive controls is important. The following cells and tissues have shown positive reactivity:

The documented reactivity is primarily with human samples, with the antibodies being developed against human TYMS protein fragments . When working with samples from other species, cross-reactivity should be validated experimentally before proceeding with full studies.

How can researchers distinguish between unmodified and 5FU-modified TYMS in experimental samples?

Distinguishing between unmodified thymidylate synthase (TS-N) and 5FU-modified thymidylate synthase (TS-F) requires specific antibodies and methodological approaches:

• Antibody selection challenges:

  • Standard commercial anti-TS antibodies recognize both unmodified and 5FU-modified forms

  • The FTS antibody (ternary complex-specific) has been developed to specifically recognize only the 5FU-modified TS

• Recommended methodological approach:

  • For separate quantification, use paired antibodies: a standard anti-TS antibody that recognizes both forms and the FTS antibody that recognizes only the modified form

  • Traditional immunoblot assays can distinguish between forms but are "tedious, requiring significant sample mass, multiple-step processing, and time"

• Potential for advanced assay development:

  • A high-throughput assay could be developed by pairing antibodies of two specificities without requiring prior protein separation

  • Liquid-based or automated assays may be developed for small sample sizes using the dual antibody approach

• Analytical value:

  • Calculating a TS-F:TS-N ratio provides a cumulative measure of 5FU intracellular effect over time

  • This quantification can aid in monitoring fluoropyrimidine cellular activity in clinical settings

This approach can potentially overcome the current limitations in distinguishing these forms for research and clinical applications.

What are the methodological considerations for using TYMS antibodies to monitor 5FU treatment response?

Using TYMS antibodies to monitor 5FU treatment response requires careful methodological consideration:

• Antibody specificity requirements:

  • Standard antibodies recognize both native and 5FU-modified TYMS, limiting their utility for monitoring drug effects

  • FTS antibody specifically recognizes 5FU-modified TS in a dose-dependent manner, making it suitable for monitoring drug activity

• Sample types and preparation:

  • The FTS antibody has been validated for use with:

    • 5FU-treated cells

    • Cancer xenograft tissues from 5FU-treated mice

    • Murine tissues

• Quantification strategies:

  • For clinical monitoring of fluoropyrimidine cellular activity, a ratio approach is recommended:

    • Measure TS-F (modified) to TS-N (remaining unmodified) ratio

    • This provides a functional assessment of drug effectiveness at the cellular level

• Assay development considerations:

  • Current immunoblot methods are labor-intensive and require substantial sample mass

  • Future directions include developing liquid-based or automated assays for small samples using dual antibody systems

  • ELISA techniques similar to those previously used with TS106 antibody could be adapted

This approach may aid in individualizing dosing regimens, potentially reducing drug resistance and toxicity issues associated with 5FU treatment.

How does antibody clone selection impact TYMS detection in different experimental contexts?

The selection of specific TYMS antibody clones significantly impacts experimental outcomes across different research contexts:

• Epitope targeting considerations:

  • Antibodies targeting different amino acid regions of TYMS show varying specificity profiles:

    • TYMS/9091R targets around aa 1-200

    • TYMS-1884 targets specifically aa 60-174

    • FTS antibody targets the 5FU-modified form

• Application-specific performance variations:

  • Different clones demonstrate varying efficacy across applications:

    • Clone 66725-1-Ig shows broad applicability in WB, IHC, IF/ICC, and FC

    • TYMS-1884 has additional validated applications in RIA and staining methods

• Isotype considerations:

  • Mouse IgG1 (66725-1-Ig) , Rabbit IgG κ , and Mouse IgG2c kappa (TYMS-1884) represent different antibody isotypes available

  • Isotype selection may impact secondary antibody compatibility and non-specific binding profiles

• Modified vs. unmodified TYMS detection:

  • Standard antibodies detect both native and 5FU-modified TYMS

  • FTS antibody specifically detects the fluorouracil-modified form

  • For drug response studies, specialized antibodies like FTS provide more relevant information

The experimental context should determine which clone is most appropriate, with consideration given to the specific form of TYMS being investigated and the detection method employed.

What are the advanced strategies for optimizing TYMS antibody performance in multi-parameter flow cytometry?

Optimizing TYMS antibody performance in multi-parameter flow cytometry requires consideration of several technical factors:

• Sample preparation for intracellular staining:

  • TYMS is primarily detected through intracellular staining, with validated protocols for HepG2 cells

  • Recommended concentration: 0.25 μg per 10^6 cells in a 100 μl suspension

  • Permeabilization protocol effectiveness is critical for intracellular target accessibility

• Panel design considerations:

  • When incorporating TYMS detection in multi-parameter panels:

    • Consider spectral overlap with other fluorophores

    • Evaluate compensation requirements based on antibody brightness

    • Place TYMS on appropriate channels based on expected expression level

• Controls for validation:

  • Positive controls: Use cell lines with confirmed TYMS expression (HepG2, Jurkat cells)

  • Negative controls: Include appropriate isotype controls (IgG1 for clone 66725-1-Ig)

  • Fluorescence-minus-one (FMO) controls are essential for accurate gating

• Quantitative assessment:

  • Consider the relationship between 5FU treatment and TYMS detection

  • For treatment monitoring applications, inclusion of both modified and unmodified TYMS-specific antibodies may provide more comprehensive data

  • Methodological validation is required when transitioning from qualitative to quantitative flow cytometry for TYMS

Multi-parameter flow cytometry approaches allow researchers to correlate TYMS expression with other cellular markers, potentially revealing mechanisms of drug response or resistance.

How can dual-antibody approaches be developed for quantifying the ratio of native to modified TYMS?

Developing dual-antibody approaches for quantifying the ratio of native to 5FU-modified TYMS represents an advanced research direction with significant clinical potential:

• Theoretical framework:

  • A paired antibody system requires:

    • One antibody specific to 5FU-modified TYMS (e.g., FTS antibody)

    • One antibody recognizing both modified and unmodified TYMS

    • Mathematical model to calculate the ratio of modified to unmodified forms

• Current methodological limitations:

  • Existing quantification based on immunoblotting is "tedious, requiring significant sample mass, multiple-step processing, and time"

  • Separate detection of the two forms currently requires protein separation techniques

• Proposed assay development strategy:

  • Using the "separate quantification of TS and TS-F, it would be possible to calculate a TS-F:TS-N ratio as a cumulative measure of 5FU intracellular effect over time"

  • Development of liquid-based or automated assays suitable for small sample sizes could be achieved by adapting existing ELISA technologies

• Potential clinical applications:

  • Such assays could permit "functional monitoring of the effectiveness of a dose of 5FU or response to 5FU in the clinic, obtaining samples by biopsy or at the time of tumor resection"

  • This approach may facilitate individual tailoring of dosing, addressing current challenges of drug resistance and toxicity

The development of such dual-antibody quantification systems represents a promising direction for translational research with potential clinical impact in personalized cancer treatment strategies.